skip to content

 

The Department's buildings are currently open for wet laboratory work only. We have carried out a comprehensive COVID-19 risk assessment process and have introduced a number of new measures to ensure the safety of our staff, including reduced building occupancy, strict social distancing, 'family'-based working, and increased cleaning and hygiene regimes. All staff who can work remotely will do so for the foreseeable future. Please continue to contact us by email until further notice.

Department of Biochemistry

 
Illustration of the SARS-CoV-2 virus.
Read more at: Modulation of host cell RNA-binding proteins through the infectious cycle of SARS-CoV-2
Schematic representation of the OOPS method.

Modulation of host cell RNA-binding proteins through the infectious cycle of SARS-CoV-2

Kathryn Lilley and her long-term collaborator, Anne Willis (MRC Toxicology Unit), have formed an international consortium of researchers, along with collaborators from the pharmaceutical industry, to interrogate host protein-viral RNA interactions.


Read more at: Analysing the human-coronavirus RNA interactome
Illustration of the SARS-CoV-2 virus.

Analysing the human-coronavirus RNA interactome

Omer Ziv and his colleagues are employing cutting-edge tools to dissect the crosstalk between human and coronavirus RNA.


Read more at: COVID-19 diagnostics for Africa
Dr Samir Hamaia in the laboratory.

COVID-19 diagnostics for Africa

The Jackson Group are part of a wider consortium that includes researchers from Cambridge, continental Europe and Africa that together will develop and test in clinical settings assays for the detection of SARS-CoV-2 virus RNA and exposure to COVID-19 in patients.


Read more at: Development of multiplex serological assays for evaluation of SARS-CoV-2 immunity
Illustration of the SARS-CoV-2 virus.

Development of multiplex serological assays for evaluation of SARS-CoV-2 immunity

The Hyvönen Group and their collaborators are producing and utilising SARS-CoV-2 proteins to employ FBAR sensor technology for COVID-19 serological tests.


Read more at: Targeting conserved RNA elements in SARS-CoV-2 for therapy
Members of the Luisi Group in the laboratory during lockdown.

Targeting conserved RNA elements in SARS-CoV-2 for therapy

The Luisi Group and a large team of international collaborators are working to develop drugs against the SARS-CoV-2 virus, focusing particularly on the highly-structured, highly-conserved s2m RNA element.


Read more at: Affinity reagents for functional neutralisation of nCoV-19
Illustration of the SARS-CoV-2 virus.

Affinity reagents for functional neutralisation of nCoV-19

The Hollfelder Group are using directed evolution to select for proteins with potential viral binding properties for use in diagnostic assays or as antiviral drugs.


Read more at: Structural and computational biology of COVID-19
SARS-CoV-2-human protein-protein interactions.

Structural and computational biology of COVID-19

The Blundell Group are using multifaceted approaches to identify potential drug targets and inhibitors against SARS-CoV-2.